Physician profile
Michael A Connor
NPI 1356439020
$1,887.84
in general payments reported to CMS, 2019-2025
15 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $71.60 · 2021: $67.68 · 2022: $493 · 2023: $177 · 2024: $101 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $457.91 | 2022 | |
| Abbvie INC. | $297.81 | 2023-2025 | Botox |
| Allergan, INC. | $221.48 | 2019-2022 | |
| Sight Sciences, INC. | $212.03 | 2019 | |
| Kala Pharmaceuticals, INC. | $122.55 | 2019 | |
| Aerie Pharmaceuticals, INC. | $105.11 | 2019 | |
| Novartis Pharmaceuticals Corporation | $103.52 | 2019 | |
| Sun Pharmaceutical Industries INC. | $84.06 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $80.84 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $59.46 | 2024 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $53.07 | 2019-2021 | |
| Galderma Laboratories, L.P. | $28.66 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $21.03 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $20.91 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.